Skip to main content
Monday, August 24, 2026
BTC $79,053 ▲ 1.69%
GOKHSHTEIN
.
Live Wire
Politics
World
Markets
Digital Assets
Technology
Sports
Sections
Franchises
The Brief
The Big Read
The Breakdown
Crypto Culture
More Sections
DeFi & On-Chain
U.S. Equities
Macro & Rates
Research
Subscribe
Menu
×
News
Live Wire
Politics
World
Markets
Digital Assets
Technology
Sports
Franchises
The Brief
The Big Read
The Breakdown
Crypto Culture
More
DeFi & On-Chain
U.S. Equities
Macro & Rates
Research
Subscribe
LIVE
ADA
$0.222
down
−2.24%
ETH
$2,476
up
+0.55%
LINK
$11.55
up
+0.10%
SOL
$96.21
up
+0.83%
BTC
$79,053
up
+1.69%
XRP
$1.50
down
−1.12%
S&P 500
7,660
down
−0.19%
Nasdaq
26,070
down
−0.42%
Dow
53,388
up
+0.21%
RUT
2,999
down
−0.63%
TNX
4.69%
down
−0.97%
TYX
5.22%
down
−1.12%
FVX
4.40%
down
−0.47%
IRX
3.71%
down
−0.08%
VIX
15.68
up
+3.64%
GOLD
$4,715.10
up
+0.74%
SILVER
$68.80
down
−1.05%
OIL
$85.32
down
−2.00%
DXY
98.99
up
+0.19%
NVDA
$209.68
down
−2.35%
AAPL
$313.10
up
+1.21%
TSLA
$354.92
down
−2.19%
META
$557.87
up
+1.45%
MSFT
$489.23
up
+1.24%
AMZN
$262.99
up
+1.68%
GOOGL
$351.05
up
+1.81%
Fear & Greed
73 — Greed
ADA
$0.222
down
−2.24%
ETH
$2,476
up
+0.55%
LINK
$11.55
up
+0.10%
SOL
$96.21
up
+0.83%
BTC
$79,053
up
+1.69%
XRP
$1.50
down
−1.12%
S&P 500
7,660
down
−0.19%
Nasdaq
26,070
down
−0.42%
Dow
53,388
up
+0.21%
RUT
2,999
down
−0.63%
TNX
4.69%
down
−0.97%
TYX
5.22%
down
−1.12%
FVX
4.40%
down
−0.47%
IRX
3.71%
down
−0.08%
VIX
15.68
up
+3.64%
GOLD
$4,715.10
up
+0.74%
SILVER
$68.80
down
−1.05%
OIL
$85.32
down
−2.00%
DXY
98.99
up
+0.19%
NVDA
$209.68
down
−2.35%
AAPL
$313.10
up
+1.21%
TSLA
$354.92
down
−2.19%
META
$557.87
up
+1.45%
MSFT
$489.23
up
+1.24%
AMZN
$262.99
up
+1.68%
GOOGL
$351.05
up
+1.81%
Fear & Greed
73 — Greed
Tag
Biotech
3 articles
U.S. Equities
2d ago
Moderna Stock Drops 25% on Cancer Vaccine Success—Wall Street's Skepticism Shows Risk
Investors sold despite positive melanoma vaccine trial results, pointing to lingering doubts about Moderna's ability to execute beyond COVID and generate sustainable returns.
Research & Analysis
5d ago
Merck, Moderna's mRNA Melanoma Vaccine Succeeds in Phase 3 Trial
Intismeran, combined with Keytruda, reduced melanoma recurrence—the first neoantigen vaccine to clear a late-stage randomized trial.
DeFi & On-Chain
18d ago
Self-Driving Labs Lift Consumables Demand, Split Fortunes Between Commodity and Scarce Inputs
AI-powered labs are expanding total experiment volume, pressuring commodity labware suppliers while strengthening the market position of scarce reagents and specialized inputs.